CommercialCoverageMedium impact
Siltuximab (Sylvant) (CPB 0884, reviewed 2026-06-03)
Aetna·Oncology, Hematology, Critical Care +1 more·Medical Policy
Effective date
Jun 3, 2026
We identified it
Aug 16, 2026
Summary
Aetna updated its coverage policy for siltuximab (Sylvant) effective June 3, 2026, establishing medical necessity criteria for two primary indications: Castleman's disease (multicentric and unicentric relapsed/refractory forms) and cytokine release syndrome (including CAR T-cell, lymphocyte engager, and KSHV-associated). The policy also clarifies continuation of therapy requirements and designates 20+ other cancer and inflammatory conditions as experimental/investigational. Billing teams must verify member eligibility against specific disease criteria before claim submission.
Action Required
By June 3, 2026: Billing team must implement prior authorization verification for siltuximab (Sylvant) claims. (1) Update billing system to require clinical verification that claims include one of the covered ICD-10 codes (D47.Z2 for Castleman's disease or D89.831-D89.839 for cytokine release syndrome). (2) Reject or hold claims containing excluded ICD-10 codes (e.g., C50.011-C50.929 for breast cancer, C34.00-C34.92 for non-small cell lung cancer, M05.00-M06.9 for rheumatoid arthritis) as these are experimental/investigational. (3) Train billing staff that J2860 (siltuximab injection) claims must include supporting documentation confirming: for Castleman's disease—multicentric or unicentric relapsed/refractory status AND HIV-1 negative and HHV-8 negative status; for CRS—Grade 4 refractory to high-dose corticosteroids, tocilizumab supply limitation, or lymphocyte engager-related toxicity grades 2-4. (4) Update claim submission templates to include disease status and biomarker results (HIV/HHV-8 status). (5) Flag any claims for non-covered indications (20+ cancers and inflammatory conditions listed) for immediate denial. Failure to implement these controls will result in claim denials and potential overpayment recoupture.